Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 14/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 14/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | HRH2 | P25021 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR5A | P47898 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099892 | 1.00 | TMEM97 (0.48) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 | |
| SCHEMBL16143784 | 1.00 | TMEM97 (0.48) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 | |
| SCHEMBL10174845 | 0.90 | TMEM97 (0.48) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 | |
| SCHEMBL8175192 | 0.86 | FKBP1A (0.47) | PREPNPC1RAB9ANPSR1 | |
| SCHEMBL12187905 | 0.85 | ABHD6 (0.39) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 | |
| SCHEMBL12164472 | 0.85 | ABHD6 (0.39) | TMEM97SIGMAR1ADRA2AADRA2BHRH2 | |
| SCHEMBL3748218 | 0.83 | PRMT5 (0.47) | NPC1RAB9A | |
| SCHEMBL2612174 | 0.83 | PRMT5 (0.47) | NPC1RAB9A | |
| SCHEMBL2102201 | 0.82 | NOTUM (0.45) | NPC1RAB9AL3MBTL1 | |
| SCHEMBL2102200 | 0.82 | NOTUM (0.45) | NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8529882-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252923-B2 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820671-B2 | Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
| US-20100137583-A1 | Peptidomimetic protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137583-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | TMEM97 1796/4885SIGMAR1 1810/4885ADRA2A 4283/4885 |
| US-20120064034-A1 | Peptidomimetic protease inhibitors | CTSC, PREP, PEPD | TMEM97 1796/4885SIGMAR1 1810/4885ADRA2A 4283/4885 |
| US-20120282219-A1 | PEPTIDOMIMETIC PROTEASE INHIBITORS | CTSC, PEPD, PREP | TMEM97 2358/4885SIGMAR1 2168/4885ADRA2A 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.